NCT02218125 (MENSCH) is a Phase 1 clinical trial of MVA Mosaic in Healthy, sponsored by Crucell Holland BV.

Who is sponsoring NCT02218125?

NCT02218125 is sponsored by Crucell Holland BV.

What drugs are being tested in NCT02218125?

Interventions in NCT02218125: MVA Mosaic, Placebo.

Is NCT02218125 still recruiting?

NCT02218125 is currently completed. Last updated 27 November 2018.

Last reviewed 2018-11-27 · How we verify

NCT02218125: MENSCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Completed Phase 1 Last updated 27 November 2018

What this trial tests

Phase 1 trial testing MVA Mosaic in Healthy in 25 participants. Completed in 30 November 2015.

Timeline

23 September 2014

Primary endpoint
30 November 2015

30 November 2015

Quick facts

Lead sponsor	Crucell Holland BV
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	25
Start date	23 September 2014
Primary completion	30 November 2015
Estimated completion	30 November 2015
Sites	1 location across United States

Drugs / interventions tested

MVA Mosaic — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Crucell Holland BV — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Progress in HIV vaccine development.
Hsu DC, O'Connell RJ. · · 2017 · cited 62× · PMID 28281871 · DOI 10.1080/21645515.2016.1276138
New concepts in HIV-1 vaccine development.
Stephenson KE, D'Couto HT, Barouch DH. · · 2016 · cited 58× · PMID 27268856 · DOI 10.1016/j.coi.2016.05.011
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Baden LR, Walsh SR, Seaman MS, Cohen YZ, et al · · 2018 · cited 37× · PMID 29669026 · DOI 10.1093/infdis/jiy212
Vaccinia virus-based vector against infectious diseases and tumors.
Zhang Z, Dong L, Zhao C, Zheng P, et al · · 2021 · cited 33× · PMID 33606578 · DOI 10.1080/21645515.2020.1840887
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Libera M, Caputo V, Laterza G, Moudoud L, et al · · 2024 · cited 9× · PMID 38628675 · DOI 10.1155/2024/2147912

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Crucell Holland BV trials

Trials by the same sponsor.

NCT02543268 — A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participa · Phase 3 · completed
NCT02440035 — A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in He · Phase 1 · completed
NCT02313077 — A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants · Phase 1 · completed
NCT01938352 — Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge · Phase 2 · completed
NCT01307436 — Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02218125 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Crucell Holland BV
Last refreshed: 27 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02218125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing